Karyopharm Therapeutics Inc (NAS:KPTI)
$ 1.09 0.02 (1.87%) Market Cap: 126.95 Mil Enterprise Value: 112.52 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 76/100

Karyopharm Therapeutics Inc at Canaccord Genuity Horizons in Oncology Conference (Virtual) Transcript

Apr 14, 2022 / 01:30PM GMT
Release Date Price: $7.8 (-3.11%)
Arlinda Lee
Canaccord Genuity LLC - Analyst

Good morning. My name is Arlinda Lee, and I'm a Senior Biotech Analyst at Canaccord Genuity. It's my pleasure to introduce the members of the management team at Karyopharm Therapeutics. With us today are Paul Richard -- sorry. I do this all the time, I'm sorry -- Richard Paulson, the President and CEO; Patricia Judson, the SVP of Medical Strategy; and Mike Mason, the Chief Financial Officer. Team, thanks for joining us today.

Richard Paulson
Karyopharm Therapeutics Inc. - President & CEO

Thank you, Arlinda. It's great to see you. And thanks to Canaccord for hosting us at the event today. Good morning, everyone, and thank you for being here as well. Maybe I'll just share a few comments and a few slides and then we can go into the Q&A. So before we begin, please see our Safe Harbor disclaimer. Various remarks we'll make today do constitute forward-looking statements, and actual results may differ materially from those indicated by these statements.

So at Karyopharm, we are leveraging the inhibition

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot